Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Gilead (GILD) Drugs Get Positive CHMP Opinion for Label Expansion
01:28pm, Monday, 19'th Sep 2022 Zacks Investment Research
Gilead's (GILD) COVID-19 treatment Veklury and CAR T-cell therapy Yescarta get positive CHMP recommendation for additional indications.
The Zacks Analyst Blog Highlights AbbVie, Novartis, Merck and AstraZeneca
10:43am, Monday, 19'th Sep 2022 Zacks Investment Research
AbbVie, Novartis, Merck and AstraZeneca are included in this Analyst Blog.
2 Best Healthcare Stocks to Buy Right Now
10:45am, Sunday, 18'th Sep 2022
The healthcare sector typically performs well in all kinds of economic environments.
4 Large Drug Stocks to Watch as Fundamentals Stay Strong
01:58pm, Friday, 16'th Sep 2022 Zacks Investment Research
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novartis (NVS), Merck (MRK) and AstraZeneca (AZN) are wor
A 'Game-Changing' Tool In Prostate Cancer Stokes A Huge Gain For Lantheus Stock
08:00am, Friday, 16'th Sep 2022
Lantheus Holdings' Definity continues to grow. But its new Pylarify imaging tool underpins triple-digit gains for LNTH stock.
Novartis says authorities investigating a patent assertion
06:34am, Thursday, 15'th Sep 2022 MarketWatch
The probe into Novartis's assertion of a patent in the broader field of dermatology treatments doesn't imply wrongdoing or financial impact, the company said.
Novartis says it is subject of Swiss competition probe
01:44am, Thursday, 15'th Sep 2022
Novartis is the subject of an investigation by the Swiss competition commission into patent use, the Swiss pharmaceutical company said on Thursday.
Swiss competition watchdog probes Novartis over patent use
01:15am, Thursday, 15'th Sep 2022
The Swiss competition commission (COMCO) has opened an investigation of Novartis over possible unlawful use of a patent to reduce competitive pressure, the Swiss drugmaker confirmed on Thursday.
A Major October Catalyst Could Make This Eye Stock A Ten Bagger, Analyst Says
06:01pm, Tuesday, 13'th Sep 2022 Benzinga
Chardan initiated coverage on Outlook Therapeutics Inc (NASDAQ: OTLK) with a Buy rating and a price target of $10 based on the company's commercial potential with its lead ophthalmic formulation o
5 Good Companies Selling for a Pittance
10:56am, Monday, 12'th Sep 2022
A difficult economic environment such as the one we are currently experiencing provides the best time to find good investments at a discount, because paying the right price has a significant influence
Novartis plans to close a Sandoz plant in North Carolina
07:50am, Friday, 09'th Sep 2022
Pharmaceuticals company Novartis plans to close a Sandoz generics plant in Wilson, North Carolina, around the end of 2023, it said on Friday, citing inability to use the U.S. site to full capacity.
This Overlooked Danger Could Tank Big Pharma Stocks
06:13pm, Thursday, 01'st Sep 2022
It started out relatively small, or as small as a recall of one of the first drugs to top $1 billion in annual sales can be. In September 2019, individual companies began recalling popular heartburn m
Pharma Stock Roundup: FDA Authorization of Omicron Boosters, SNY's Xenpozyme & More
02:41pm, Thursday, 01'st Sep 2022 Zacks Investment Research
FDA authorizes Pfizer (PFE) & Moderna's (MRNA) Omicron-aimed COVID vaccines & Sanofi's (SNY) new drug, Xenpozyme.
Novartis taps MSD exec Marshall to replace Bradner as research head
01:17am, Thursday, 01'st Sep 2022
Novartis appointed Merck executive Fiona Marshall as president of the Novartis Institutes for Biomedical Research to replace Jay Bradner, who is stepping down as research head at the Swiss drugmaker,
Novartis (NVS) Chronic Myeloid Leukemia Drug Approved by EC
04:17pm, Tuesday, 30'th Aug 2022 Zacks Investment Research
Novartis (NVS) strengthens its oncology portfolio with EC approval for its chronic myeloid leukemia drug, Scemblix.
